Printer Friendly

Prima Biomed Ltd reports start of CANVAS (CANcer VAccine Study) clinical trial in Ukraine, Europe.

M2 EQUITYBITES-February 28, 2013-Prima Biomed Ltd reports start of CANVAS (CANcer VAccine Study) clinical trial in Ukraine, Europe(C)2013 M2 COMMUNICATIONS

Biotechnology company Prima BioMed Ltd (ASX :PRR) (NASDAQ:PBMD ) stated on Wednesday that it has initiated the recruitment of patients into the CANVAS (CANcer VAccine Study) trial at several centres in the Ukraine, Europe.

The company said that it has obtained the requisite ethics and regulatory approvals in multiple European countries, including Belarus, Belgium, Bulgaria, Germany, Lithuania, Latvia, Poland and Ukraine. It expects the majority of CANVAS patients will be enrolled in Europe. The trial is currently open for recruitment at a number of centres in the US and Australia.

This CANcer VAccine Study (CANVAS) is reportedly a multi-centre, randomised, placebo-controlled study of CVac in mucin 1 positive, epithelial ovarian cancer patients who have undergone optimal surgery and achieve complete remission after first-line chemotherapy. About 1000 patients will be recruited at over 100 hospitals throughout Australia, the USA, Europe and Asia to have 800 evaluable study patients undergo dosing.

According to the company, the study objectives are to ascertain if CVac, as compared to a placebo, is able to improve the time patients remain in remission before tumour progression (progression-free survival) and extend overall survival of patients. Safety parameters, quality of life impact, manufacturing quality and additional laboratory assessments will be investigated.

((Comments on this story may be sent to

COPYRIGHT 2013 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2013 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Geographic Code:4EXUR
Date:Feb 28, 2013
Previous Article:Lancaster Colony's board declares cash dividend of USD0.38.
Next Article:Dex One receives delisting notice from NYSE; plans appeal.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters